Complete Response in a Hodgkin’s Lymphoma with a Non-Hodgkin’s Lymphoma regimen! - R-CHOP chemotherapy in Stage IV Nodular Lymphocyte Predominant Hodgkin's Lymphoma
Location
Culp Center Ballroom
Start Date
4-25-2023 9:00 AM
End Date
4-25-2023 11:00 AM
Poster Number
87
Faculty Sponsor’s Department
Other - please list
Medical Oncology
Name of Project's Faculty Sponsor
Devapiran Jaishankar
Competition Type
Competitive
Type
Poster Presentation
Project's Category
Lymphomas
Abstract or Artist's Statement
Nodular lymphocyte predominant Hodgkin's lymphoma (NLPHL) is a rare and unique subtype of Hodgkin's lymphoma (HL), accounting for approximately 5% of HL. On histology, NLPHL presents with “popcorn cells” composed of lymphocytic and histiocytic cells that express CD20 and CD45, unlike the pathognomonic Reed-Sternberg cells in classic HL (cHL) that express CD15 and CD30. Such differences in histopathology may require alternative treatment approaches. We present a rare case of NLPHL with atypical features at presentation with excellent response to treatment regimen used in Non Hodgkin’s Lymphoma (NHL).
A 36-year-old male presented with acute onset back pain. He also noted multiple gradually enlarging lumps in his neck, axilla, and anterior chest wall for a few months. He mentioned significant constitutional symptoms including fatigue, weight loss, and drenching night sweats. No evidence of end-organ damage was present, except significant hypercalcemia suggestive of hypercalcemia of malignancy. An excisional biopsy of his axillary lymph node confirmed the diagnosis of NLPHL with immuno-stains that were positive for CD20, CD45 and negative for CD15 and CD30. PET scan demonstrated extensive tumor burden in the skeletal system, including the sternum, and multi-stationary lymphadenopathy. Splenomegaly with lymphomatous infiltration was also present. He was assigned stage IV based on the Ann Arbor staging system. R-CHOP (rituximab, cyclophosphamide, doxorubicin, vincristine, prednisone) was initiated with a goal of 6 cycles, differing from ABVD (adriamycin, bleomycin, vinblastine, dacarbazine) regimen that is used for cHL. Interval PET scan post 4 cycles of R-CHOP showed no evidence of residual disease. PET scan after 6 cycles demonstrated a complete response (CR), including resolution of hypermetabolic uptake in the spleen, lymph nodes and bones.
NLPHL is often considered indolent in clinical courses but with a tendency for multiple late relapses compared to cHL. It still maintains a favorable prognosis. In contrast to cHL, NLPHL less frequently presents with constitutional symptoms, increased tumor burden, or at an advanced stage, which is associated with a worse prognosis.
Our patient had multiple features that are unusual in NLPHL such as hypercalcemia, extensive bony involvement with hypermetabolic lytic lesions and significant constitutional symptoms. The clinical conundrum with this rare subtype is whether to treat with HL vs NHL regimens. Literature and the guidelines recommend a conservative approach for low stage NLPHL with observation vs radiation vs single agent rituximab (used in NHL!). Advanced stages require multi-agent regimens ranging from one end of the spectrum with ABVD (used in cHL) to the other end with R-CHOP and its variants (used in NHL). Our patient with a rare subtype of HL had a very unusual and aggressive presentation with CR to R-CHOP demonstrating that rituximab based regimens should be the mainstay of treatment.
Complete Response in a Hodgkin’s Lymphoma with a Non-Hodgkin’s Lymphoma regimen! - R-CHOP chemotherapy in Stage IV Nodular Lymphocyte Predominant Hodgkin's Lymphoma
Culp Center Ballroom
Nodular lymphocyte predominant Hodgkin's lymphoma (NLPHL) is a rare and unique subtype of Hodgkin's lymphoma (HL), accounting for approximately 5% of HL. On histology, NLPHL presents with “popcorn cells” composed of lymphocytic and histiocytic cells that express CD20 and CD45, unlike the pathognomonic Reed-Sternberg cells in classic HL (cHL) that express CD15 and CD30. Such differences in histopathology may require alternative treatment approaches. We present a rare case of NLPHL with atypical features at presentation with excellent response to treatment regimen used in Non Hodgkin’s Lymphoma (NHL).
A 36-year-old male presented with acute onset back pain. He also noted multiple gradually enlarging lumps in his neck, axilla, and anterior chest wall for a few months. He mentioned significant constitutional symptoms including fatigue, weight loss, and drenching night sweats. No evidence of end-organ damage was present, except significant hypercalcemia suggestive of hypercalcemia of malignancy. An excisional biopsy of his axillary lymph node confirmed the diagnosis of NLPHL with immuno-stains that were positive for CD20, CD45 and negative for CD15 and CD30. PET scan demonstrated extensive tumor burden in the skeletal system, including the sternum, and multi-stationary lymphadenopathy. Splenomegaly with lymphomatous infiltration was also present. He was assigned stage IV based on the Ann Arbor staging system. R-CHOP (rituximab, cyclophosphamide, doxorubicin, vincristine, prednisone) was initiated with a goal of 6 cycles, differing from ABVD (adriamycin, bleomycin, vinblastine, dacarbazine) regimen that is used for cHL. Interval PET scan post 4 cycles of R-CHOP showed no evidence of residual disease. PET scan after 6 cycles demonstrated a complete response (CR), including resolution of hypermetabolic uptake in the spleen, lymph nodes and bones.
NLPHL is often considered indolent in clinical courses but with a tendency for multiple late relapses compared to cHL. It still maintains a favorable prognosis. In contrast to cHL, NLPHL less frequently presents with constitutional symptoms, increased tumor burden, or at an advanced stage, which is associated with a worse prognosis.
Our patient had multiple features that are unusual in NLPHL such as hypercalcemia, extensive bony involvement with hypermetabolic lytic lesions and significant constitutional symptoms. The clinical conundrum with this rare subtype is whether to treat with HL vs NHL regimens. Literature and the guidelines recommend a conservative approach for low stage NLPHL with observation vs radiation vs single agent rituximab (used in NHL!). Advanced stages require multi-agent regimens ranging from one end of the spectrum with ABVD (used in cHL) to the other end with R-CHOP and its variants (used in NHL). Our patient with a rare subtype of HL had a very unusual and aggressive presentation with CR to R-CHOP demonstrating that rituximab based regimens should be the mainstay of treatment.